{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:00:52Z","timestamp":1740142852590,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"crossref","award":["R01 MH106682"],"award-info":[{"award-number":["R01 MH106682"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006545","name":"National Institute of Minority Health and Health Disparities","doi-asserted-by":"crossref","award":["R01 MDO12428"],"award-info":[{"award-number":["R01 MDO12428"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adm Policy Ment Health"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10488-021-01141-7","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T15:21:03Z","timestamp":1621437663000},"page":"59-70","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Significance and Factors Associated with Antipsychotic Polypharmacy Utilization Among Publicly Insured US Adults"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8120-9313","authenticated-orcid":false,"given":"Marcela","family":"Horvitz-Lennon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Volya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katya","family":"Zelevinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie M.","family":"Donohue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Mulcahy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon-Lise T.","family":"Normand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"1141_CR1","doi-asserted-by":"publisher","unstructured":"Association, A. P. (2020). The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia (0890424691). Retrieved from https:\/\/doi.org\/10.1176\/appi.books.9780890424841","DOI":"10.1176\/appi.books.9780890424841"},{"issue":"1","key":"1141_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/0003-4819-158-1-201301010-00560","volume":"158","author":"DW Baker","year":"2013","unstructured":"Baker, D. W., Qaseem, A., Reynolds, P. P., Gardner, L. A., & Schneider, E. C. (2013). Design and use of performance measures to decrease low-value services and achieve cost-conscious care. Annals of Internal Medicine, 158(1), 55\u201359. https:\/\/doi.org\/10.7326\/0003-4819-158-1-201301010-00560","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"1141_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881119889296","volume":"34","author":"TR Barnes","year":"2020","unstructured":"Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., & Joyce, E. M. (2020). Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 34(1), 3\u201378","journal-title":"Journal of Psychopharmacology"},{"issue":"9","key":"1141_CR4","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1176\/appi.ps.62.9.1004","volume":"62","author":"MF Brunette","year":"2011","unstructured":"Brunette, M. F., de Nesnera, A., Swain, K., Riera, E. G., Lotz, D., & Bartels, S. J. (2011). Public-academic partnerships: A program to improve the quality of antipsychotic prescribing in a community mental health system. Psychiatric Services, 62(9), 1004\u20131006. https:\/\/doi.org\/10.1176\/appi.ps.62.9.1004","journal-title":"Psychiatric Services"},{"key":"1141_CR5","unstructured":"Bureau of Labor Statistics. (2019, December 2). Databases, Tables & Calculators by Subject. PPI industry data for Pharmaceutical preparation manufacturing, not seasonally adjusted. Retrieved from https:\/\/data.bls.gov\/pdq\/SurveyOutputServlet"},{"issue":"1","key":"1141_CR6","first-page":"35","volume":"42","author":"AB Busch","year":"2009","unstructured":"Busch, A. B., Frank, R. G., Sachs, G., & Normand, S. L. (2009). Bipolar-I patient characteristics associated with differences in antimanic medication prescribing. Psychopharmacology Bulletin, 42(1), 35\u201349","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"1141_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra1906193","volume":"383","author":"AF Carvalho","year":"2020","unstructured":"Carvalho, A. F., Firth, J., & Vieta, E. (2020). Bipolar disorder. New England Journal of Medicine, 383(1), 58\u201366. https:\/\/doi.org\/10.1056\/NEJMra1906193","journal-title":"New England Journal of Medicine"},{"key":"1141_CR8","unstructured":"Centers for Medicare & Medicaid Services. (2008). Medicare Prescription Drug Benefit Manual, Chapter 6. Baltimore, MD."},{"key":"1141_CR9","unstructured":"Centers for Medicare & Medicaid Services. (2020). Adult Core Set Reporting Resources. Baltimore, MD: Medicaid.gov. Retrieved from https:\/\/www.medicaid.gov\/medicaid\/quality-of-care\/performance-measurement\/adult-and-child-health-care-quality-measures\/adult-core-set-reporting-resources\/index.html"},{"issue":"11","key":"1141_CR10","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2217\/pgs.13.127","volume":"14","author":"LF Chan","year":"2013","unstructured":"Chan, L. F., Zai, C., Monda, M., Potkin, S., Kennedy, J. L., Remington, G., Lieberman, J., Meltzer, H. Y., & De Luca, V. (2013). Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: Genes or environment? Pharmacogenomics, 14(11), 1273\u20131281","journal-title":"Pharmacogenomics"},{"issue":"6","key":"1141_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10597-009-9288-2","volume":"46","author":"R Constantine","year":"2010","unstructured":"Constantine, R., Andel, R., & Tandon, R. (2010). Trends in adult antipsychotic polypharmacy: Progress and challenges in florida\u2019s medicaid program. Community Mental Health Journal, 46(6), 523\u2013530. https:\/\/doi.org\/10.1007\/s10597-009-9288-2","journal-title":"Community Mental Health Journal"},{"issue":"1","key":"1141_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/wps.20187","volume":"14","author":"CU Correll","year":"2015","unstructured":"Correll, C. U., Joffe, B. I., Rosen, L. M., Sullivan, T. B., & Joffe, R. T. (2015). Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry, 14(1), 56\u201363. https:\/\/doi.org\/10.1002\/wps.20187","journal-title":"World Psychiatry"},{"key":"1141_CR13","unstructured":"Cubanski, J., Rae, M., Young, K., & Damico, A. (2019). How does prescription drug spending and use compare across large employer plans, medicare part D, and medicaid? Retrieved from https:\/\/www.kff.org\/medicare\/issue-brief\/how-does-prescription-drug-spending-and-use-compare-across-large-employer-plans-medicare-part-d-and-medicaid\/"},{"issue":"1\u20133","key":"1141_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.schres.2008.07.006","volume":"105","author":"GL Daumit","year":"2008","unstructured":"Daumit, G. L., Goff, D. C., Meyer, J. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P., Rosenheck, R., Davis, S. M., Hsiao, J. K., Stroup, T. S., & Lieberman, J. A. (2008). Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research, 105(1\u20133), 175\u2013187","journal-title":"Schizophrenia Research"},{"issue":"3","key":"1141_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.pcad.2014.07.006","volume":"57","author":"ML Daviglus","year":"2014","unstructured":"Daviglus, M. L., Pirzada, A., & Talavera, G. A. (2014). Cardiovascular disease risk factors in the Hispanic\/Latino population: lessons from the Hispanic Community Health Study\/Study of Latinos (HCHS\/SOL). Progress in Cardiovascular Diseases, 57(3), 230\u2013236. https:\/\/doi.org\/10.1016\/j.pcad.2014.07.006","journal-title":"Progress in Cardiovascular Diseases"},{"issue":"17","key":"1141_CR16","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1001\/jama.2012.14517","volume":"308","author":"ML Daviglus","year":"2012","unstructured":"Daviglus, M. L., Talavera, G. A., Avil\u00e9s-Santa, M. L., Allison, M., Cai, J., Criqui, M. H., Gellman, M., Giachello, A. L., Gouskova, N., Kaplan, R. C., & LaVange, L. (2012). Prevalence of major cardiovascular risk factors and cardiovascular diseases among Hispanic\/Latino individuals of diverse backgrounds in the United States. JAMA, 308(17), 1775\u20131784","journal-title":"JAMA"},{"issue":"3","key":"1141_CR17","first-page":"27","volume":"29","author":"C Eicheldinger","year":"2008","unstructured":"Eicheldinger, C., & Bonito, A. (2008). More accurate racial and ethnic codes for Medicare administrative data. Health Care Financing Review, 29(3), 27\u201342","journal-title":"Health Care Financing Review"},{"issue":"9","key":"1141_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1176\/appi.ps.201800052","volume":"69","author":"CA Fontanella","year":"2018","unstructured":"Fontanella, C. A., Hiance-Steelesmith, D. L., Guirgis, H., & Campo, J. V. (2018). Trends in and predictors of long-term antipsychotic polypharmacy use among Ohio medicaid patients with schizophrenia, 2008\u20132014. Psychiatric Services (washington, d. c.), 69(9), 1015\u20131020. https:\/\/doi.org\/10.1176\/appi.ps.201800052","journal-title":"Psychiatric Services (washington, d. c.)"},{"issue":"10","key":"1141_CR19","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.4088\/JCP.v65n1013","volume":"65","author":"R Ganguly","year":"2004","unstructured":"Ganguly, R., Kotzan, J. A., Miller, L. S., Kennedy, K., & Martin, B. C. (2004). Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998\u20132000. Journal of Clinical Psychiatry, 65(10), 1377\u20131388","journal-title":"Journal of Clinical Psychiatry"},{"key":"1141_CR20","unstructured":"Garfield, R., Hinton, E., Cornachione, E., & Hall, C. (2018). Medicaid Managed Care Plans and Access to Care: Results from the Kaiser Family Foundation 2017 Survey of Medicaid Managed Care Plans. Retrieved from https:\/\/www.kff.org\/medicaid\/report\/medicaid-managed-care-plans-and-access-to-care-results-from-the-kaiser-family-foundation-2017-survey-of-medicaid-managed-care-plans\/"},{"issue":"7","key":"1141_CR21","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1176\/ps.2007.58.7.1007","volume":"58","author":"TP Gilmer","year":"2007","unstructured":"Gilmer, T. P., Dolder, C. R., Folsom, D. P., Mastin, W., & Jeste, D. V. (2007). Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999\u20132004. Psychiatric Services (washington, d. c.), 58(7), 1007\u20131010. https:\/\/doi.org\/10.1176\/ps.2007.58.7.1007","journal-title":"Psychiatric Services (washington, d. c.)"},{"issue":"3","key":"1141_CR22","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1377\/hlthaff.28.3.701","volume":"28","author":"M Horvitz-Lennon","year":"2009","unstructured":"Horvitz-Lennon, M., Donohue, J. M., Domino, M. E., & Normand, S. L. T. (2009). Improving quality and diffusing best practices: The case of schizophrenia. Health Affairs (millwood), 28(3), 701\u2013712. https:\/\/doi.org\/10.1377\/hlthaff.28.3.701","journal-title":"Health Affairs (millwood)"},{"issue":"4","key":"1141_CR23","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/1475-6773.12162","volume":"49","author":"M Horvitz-Lennon","year":"2014","unstructured":"Horvitz-Lennon, M., Volya, R., Donohue, J. M., Lave, J. R., Stein, B. D., & Normand, S.-L.T. (2014). Disparities in quality of care among publicly insured adults with schizophrenia in four large US States, 2002\u20132008. Health Services Research, 49(4), 1121\u20131144. https:\/\/doi.org\/10.1111\/1475-6773.12162","journal-title":"Health Services Research"},{"key":"1141_CR24","unstructured":"Jacobson, G., Damico, A., Neuman, T., & Gold, M. (2017). Medicare Advantage 2017 Spotlight: Enrollment Market Update. Retrieved from Menlo Park: https:\/\/www.kff.org\/medicare\/issue-brief\/medicare-advantage-2017-spotlight-enrollment-market-update\/"},{"issue":"1","key":"1141_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/pds.783","volume":"12","author":"AB Jaffe","year":"2003","unstructured":"Jaffe, A. B., & Levine, J. (2003). Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiology and Drug Safety, 12(1), 41\u201348","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"7","key":"1141_CR26","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1176\/ps.2007.58.7.983","volume":"58","author":"J Kreyenbuhl","year":"2007","unstructured":"Kreyenbuhl, J., Marcus, S. C., West, J. C., Wilk, J., & Olfson, M. (2007). Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatric Services, 58(7), 983\u2013990","journal-title":"Psychiatric Services"},{"key":"1141_CR27","unstructured":"Kuramoto-Crawford, J., & Zodet, M. (2014). Behavioral health conditions and health care expenditures of adults aged 18 to 64 dually eligible for medicaid and medicare. Retrieved from Rockville, MD: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK384683\/pdf\/Bookshelf_NBK384683.pdf"},{"issue":"6","key":"1141_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/pds.1092","volume":"14","author":"BL Lambert","year":"2005","unstructured":"Lambert, B. L., Chou, C. H., Chang, K. Y., Tafesse, E., & Carson, W. (2005). Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: A matched case-control study of California Medicaid claims. Pharmacoepidemiology and Drug Safety, 14(6), 417\u2013425. https:\/\/doi.org\/10.1002\/pds.1092","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"6","key":"1141_CR29","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/pds.3609","volume":"23","author":"E Leckman-Westin","year":"2014","unstructured":"Leckman-Westin, E., Kealey, E., Gupta, N., Chen, Q., Gerhard, T., Crystal, S., Olfson, M., & Finnerty, M. (2014). Validation of a claims-based antipsychotic polypharmacy measure. Pharmacoepidemiology and Drug Safety, 23(6), 628\u2013635","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"Suppl 1","key":"1141_CR30","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","volume":"42","author":"S Leucht","year":"2016","unstructured":"Leucht, S., Samara, M., Heres, S., & Davis, J. M. (2016). Dose equivalents for antipsychotic drugs: The DDD method. Schizophrenia Bulletin, 42(Suppl 1), S90-94. https:\/\/doi.org\/10.1093\/schbul\/sbv167","journal-title":"Schizophrenia Bulletin"},{"key":"1141_CR31","unstructured":"Medicare Payment Advisory Commission. (2018). Chapter 9: Managed care plans for dual-eligible beneficiaries. In Report to the congress: Medicare and the health care delivery system (pp. 243\u2013283). Washington, DC."},{"issue":"1","key":"1141_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archgenpsychiatry.2009.175","volume":"67","author":"R Mojtabai","year":"2010","unstructured":"Mojtabai, R., & Olfson, M. (2010). National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry, 67(1), 26\u201336. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2009.175","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"1141_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.clinthera.2007.01.002","volume":"29","author":"EH Morrato","year":"2007","unstructured":"Morrato, E. H., Dodd, S., Oderda, G., Haxby, D. G., Allen, R., & Valuck, R. J. (2007). Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: Experience in a multistate Medicaid Population, 1998\u20132003. Clinical Therapeutics, 29(1), 183\u2013195","journal-title":"Clinical Therapeutics"},{"key":"1141_CR34","unstructured":"National Association of State Mental Health Program Directors Research Institute, Inc. (2012). History of HBIPS Core Measure Set. Retrieved from Falls Church, VA. http:\/\/www.nri-inc.org\/media\/1100\/2012-history-of-hbips-bhpms.pdf"},{"key":"1141_CR35","unstructured":"National Priorities Partnership. (2008). National priorities and goals: Aligning our efforts to transform America's Healthcare."},{"issue":"9","key":"1141_CR36","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/npp.2010.78","volume":"35","author":"J Nielsen","year":"2010","unstructured":"Nielsen, J., Skadhede, S., & Correll, C. U. (2010). Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology, 35(9), 1997\u20132004. https:\/\/doi.org\/10.1038\/npp.2010.78","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"1141_CR37","doi-asserted-by":"publisher","first-page":"Cd009005","DOI":"10.1002\/14651858.CD009005.pub2","volume":"6","author":"J Ortiz-Orendain","year":"2017","unstructured":"Ortiz-Orendain, J., Castiello-de Obeso, S., Colunga-Lozano, L. E., Hu, Y., Maayan, N., & Adams, C. E. (2017). Antipsychotic combinations for schizophrenia. Cochrane Database Systematic Review, 6(6), Cd009005. https:\/\/doi.org\/10.1002\/14651858.CD009005.pub2","journal-title":"Cochrane Database Systematic Review"},{"issue":"1","key":"1141_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1176\/appi.ps.57.1.21","volume":"57","author":"V Patrick","year":"2006","unstructured":"Patrick, V., Schleifer, S. J., Nurenberg, J. R., & Gill, K. J. (2006). Best practices: An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatric Services (washington, d. c.), 57(1), 21\u201323. https:\/\/doi.org\/10.1176\/appi.ps.57.1.21","journal-title":"Psychiatric Services (washington, d. c.)"},{"issue":"3","key":"1141_CR39","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1176\/appi.ps.60.3.294","volume":"60","author":"KR Stowell","year":"2009","unstructured":"Stowell, K. R., Ghinassi, F. A., Fabian, T. J., Nash, K. C., & Haskett, R. F. (2009). Best practices: An intervention to promote evidence-based prescribing at a large psychiatric hospital. Psychiatric Services (washington, d. c.), 60(3), 294\u2013296. https:\/\/doi.org\/10.1176\/appi.ps.60.3.294","journal-title":"Psychiatric Services (washington, d. c.)"},{"key":"1141_CR40","unstructured":"The Joint Commission. (2019). Measure Information Form. Specifications manual for joint commission national quality measures (v2019A). Retrieved from https:\/\/manual.jointcommission.org\/releases\/TJC2019A\/MIF0120.html"},{"key":"1141_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.4320","author":"J Tiihonen","year":"2019","unstructured":"Tiihonen, J., Taipale, H., Meht\u00e4l\u00e4, J., Vattulainen, P., Correll, C. U., & Tanskanen, A. (2019). Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.4320","journal-title":"JAMA Psychiatry"},{"key":"1141_CR42","unstructured":"U.S. Department of Health & Human Services Office of Minority Health. (2019, December 19). Diabetes and African Americans. Retrieved from https:\/\/minorityhealth.hhs.gov\/omh\/browse.aspx?lvl=4&lvlid=18"},{"key":"1141_CR43","unstructured":"U.S. Department of Health & Human Services Office of Minority Health. (2020, February 14). Heart Disease and African Americans. Retrieved from https:\/\/minorityhealth.hhs.gov\/omh\/browse.aspx?lvl=4&lvlid=19"},{"key":"1141_CR44","unstructured":"United States Government Accountability Office. (2014). Prescription Drugs: Comparison of DoD, Medicaid, and Medicare Part D Retail Reimbursemnet Prices. Retrieved from Washington, DC. https:\/\/www.gao.gov\/assets\/670\/664521.pdf"},{"key":"1141_CR45","doi-asserted-by":"publisher","unstructured":"Valuck, R. J., Morrato, E. H., Dodd, S., Oderda, G., Haxby, D. G., Allen, R., & Medicaid Pharmacotherapy Research, C. (2007). How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid Programs. Current Medical Research and Opinion 23(10), 2567\u20132576 https:\/\/doi.org\/10.1185\/030079907X233214","DOI":"10.1185\/030079907X233214"},{"issue":"2","key":"1141_CR46","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jcpt.12037","volume":"38","author":"A Ward","year":"2013","unstructured":"Ward, A., Quon, P., Abouzaid, S., Haber, N., Ahmed, S., & Kim, E. (2013). Cardiometabolic consequences of therapy for chronic schizophrenia using second-generation antipsychotic agents in a medicaid population: clinical and economic evaluation. Pharmacy and Therapeutics, 38(2), 109\u2013115","journal-title":"Pharmacy and Therapeutics"},{"key":"1141_CR47","unstructured":"Young, K. (2019). Utilization and spending trends in medicaid outpatient prescription drugs. Retrieved from http:\/\/files.kff.org\/attachment\/Issue-Brief-Utilization-and-Spending-Trends-in-Medicaid-Outpatient-Prescription-Drugs"},{"issue":"11","key":"1141_CR48","doi-asserted-by":"publisher","first-page":"p060","DOI":"10.1093\/ijnp\/pyv060","volume":"18","author":"X Zhou","year":"2015","unstructured":"Zhou, X., Keitner, G. I., Qin, B., Ravindran, A. V., Bauer, M., Del Giovane, C., & Zhang, Y. (2015). Atypical antipsychotic augmentation for treatment-resistant depression: A systematic review and network meta-analysis. International Journal of Neuropsychopharmacology, 18(11), p060","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"1","key":"1141_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1471-244X-8-19","volume":"8","author":"B Zhu","year":"2008","unstructured":"Zhu, B., Ascher-Svanum, H., Faries, D., Correll, C., & Kane, J. (2008). Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry, 8(1), 19. https:\/\/doi.org\/10.1186\/1471-244X-8-19","journal-title":"BMC Psychiatry"},{"key":"1141_CR50","unstructured":"Zur, J., Musumeci, M., & Garfield, R. (2017). Medicaid's role in financing behavioral health services for low-income individuals. Retrieved from http:\/\/files.kff.org\/attachment\/Issue-Brief-Medicaids-Role-in-Financing-Behavioral-Health-Services-for-Low-Income-Individuals"}],"container-title":["Administration and Policy in Mental Health and Mental Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10488-021-01141-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10488-021-01141-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10488-021-01141-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T18:34:19Z","timestamp":1641407659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10488-021-01141-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1141"],"URL":"https:\/\/doi.org\/10.1007\/s10488-021-01141-7","relation":{},"ISSN":["0894-587X","1573-3289"],"issn-type":[{"type":"print","value":"0894-587X"},{"type":"electronic","value":"1573-3289"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"assertion":[{"value":"26 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}